Best Imaging CRO Vendors for Clinical Trials (2026)

Who this guide is for

This guide is for clinical operations leads, imaging scientists, regulatory staff and study directors choosing an imaging partner for a trial, plus biotech teams reviewing the imaging component of a CRO proposal. It is also for teams whose earlier studies relied on local reads and now face a registration trial in which imaging carries an endpoint, and for groups building a decentralised or hybrid design in which imaging has to travel reliably from many locations into one review process.

If you are looking for imaging CRO vendors for clinical trials, treat the vendor cards and table on this page as a starting point, not a verdict. They show which imaging vendors are listed and how each profile describes its focus; they cannot tell you how a vendor performs on a protocol like yours. Use the evaluation criteria below to structure the search, and insist on a walkthrough using your own modality and indication.

What an imaging CRO does — and when you need one

An imaging CRO, often called an imaging core lab, centralises the imaging work of a trial. Its core services are site qualification and acquisition standardisation, image transfer and management, independent review of images by qualified readers, and the data handling that turns those reads into analysable endpoints. Some imaging partners also manage tracers or contrast agents for molecular imaging, coordinate across radiology departments, and support specialised modalities such as positron emission tomography, magnetic resonance, computed tomography and ultrasound.

The defining contribution is consistency. Images arrive from many sites on many scanners, and an imaging partner applies an imaging charter so that the same anatomy is acquired the same way, the same readers measure the same structures, and every step from acquisition to final read is documented for inspection. Where the protocol allows, images can be reprocessed or harmonised to reduce scanner-driven variation.

Typical trigger points are a first efficacy imaging endpoint, a regulator or protocol requiring independent review, an adaptive design in which imaging results steer dosing or cohort selection, a multi-region study with heterogeneous equipment, or an inspection finding that exposed weak imaging documentation.

The imaging charter is the document that binds all of this together, and reviewing a candidate's charter template tells you a great deal. It should specify modality and acquisition parameters, the transfer route and its service expectations, image quality criteria and what happens when they are missed, blinding rules, the reading workflow including adjudication, and the deliverables that flow to the sponsor's database. Ask to see a redacted charter from a study resembling yours; the maturity of that document, and the directness with which the vendor walks you through it, is a better selection signal than any sales conversation.

Common imaging endpoints and what they demand from a vendor

Oncology trials often measure tumour response, progression or lesion burden, which requires lesion tracking across timepoints, consistent measurement rules and careful adjudication when readers disagree. Neurology studies may measure brain structure or volume change, where long-term scanner drift, sequence harmonisation and motion artefacts dominate the technical challenge. Cardiology endpoints such as ventricular function depend on standardised acquisition windows and quantitative analysis pipelines, while ophthalmology reads of retinal imaging bring their own scoring conventions and reader training demands.

Each endpoint family stresses a different part of an imaging partner. Response assessment stresses reader governance; volumetric endpoints stress algorithm validation and reprocessing; multi-region studies stress site qualification and transfer infrastructure. Ask every candidate to describe, in their own words, what is hard about your specific endpoint and what they have put in place for it. The specificity of that answer is itself a signal.

Working alongside your CRO and other vendors

Imaging partners rarely work alone. On a full-service programme the imaging core lab sits inside a CRO's vendor chain, and the questions change: who owns the imaging charter, how image data flows between systems, whose help desk a site calls when a transfer fails, and how responsibilities are divided when a read is late. If you are contracting the imaging partner directly while a CRO runs the study, boundary ownership needs to be written down early, because the site experiences one trial, not your org chart. Ask each candidate how they have handled this split on previous programmes and what they insist on clarifying in a three-party arrangement.

Similar questions apply to interfaces with central laboratories, electronic data capture and safety systems. Confirm what the imaging vendor expects to receive from each neighbour system, what it delivers onward, and in which format, so that integration work is priced and scheduled rather than discovered mid-study.

How to evaluate an imaging CRO vendor

Therapeutic, modality and protocol fit

Imaging work is specialised. A vendor strong in oncology response assessment may not be the right fit for a neurology trial measuring brain volume, a cardiology trial measuring cardiac function, or an ophthalmology trial reading retinal scans. Ask which indications and modalities the vendor supports in live studies, how many of your planned assessments it has run before, and how it would handle protocol-specific reading requirements before you sign.

Reader qualification and review quality

Ask how readers are selected, credentialed and qualified on reference cases before touching study data, how the vendor monitors reader drift during a long trial, and how discrepancies between readers are adjudicated. Blinded independent central review, with reader independence documented, is often expected where imaging drives a primary endpoint. Ask to see the documentation package an inspector would receive.

Technology platform and algorithm validation

Ask how images move from sites into the system, what the site experience looks like, and how the vendor tracks image completeness, quality and protocol deviations. Where computer-assisted measurement or other algorithms are used, ask which are cleared for the intended use, on what populations they were validated, and how human oversight and overrides are recorded. The audit trail should show, for every value in the database, the image, the reader or algorithm and the version of any tool involved.

Turnaround and workflow integration

Different reads carry different urgency. Eligibility and safety reads may need to happen within hours, while batched efficacy reads follow the visit schedule. Ask for the vendor's commitments on turnaround per read type, how urgent cases escalate, and how results flow back into your clinical database or safety processes. Late reads are not just an inconvenience; in an adaptive design they can stall the whole study.

Data standards, transfer and archiving

Confirm support for the formats and standards your study needs, from image formats through to derived data deliverables that align with CDISC expectations for your submissions. Ask how images and read data are exported, how a complete inspection-ready archive is maintained, and what access looks like after the study closes. Retention obligations outlive the trial, and retrieving imaging archives years later is far harder than arranging transfer at closure.

Inspection readiness is worth rehearsing rather than asserting. Ask the vendor to walk through what happens when a regulator asks for the trail behind a single derived value: the source image, the transfer record, the reader assignment, the read itself, any adjudication, and the analysis derivation. Vendors who can walk that chain quickly have usually been inspected before and fixed what it exposed; vendors who describe it vaguely have not, or did not fix it.

Imaging CRO vendors at a glance

The table below lists imaging vendors whose profiles describe image review, endpoint adjudication, imaging analysis, response assessment or core lab work, so you can compare service model, footprint and study coverage before you open individual pages. The wider imaging category also contains contrast agent suppliers, scanner and imaging platform manufacturers, and academic imaging collaborations; they support trials in other ways and are not the subject of this guide.

The fields come from each vendor’s Clinical Vendor Compare profile, and blank cells mean the record is silent. Many imaging records use the same standard wording for their best fit and strengths, so the table separates vendors mainly by service model, therapeutic focus and phase coverage. A field reading Global or Generalist means the record does not narrow the footprint or areas covered; it is not evidence of breadth. Profiles summarise what a vendor publicly offers; they are not an assessment of imaging quality, and they cannot substitute for the reference checks and demonstration walks described above.

Vendor profiles

Invicro

Invicro is listed as an imaging CRO and analysis provider headquartered in the United States with a global footprint, covering Phase I to Phase IV. Its record lists endpoint consistency, specialist review and image operations as strengths, and notes that a dedicated imaging partner can add coordination overhead in studies where imaging is not central. Where to probe: ask which modalities and indications its analysis teams support today, and how its reads feed your clinical database.

IXICO

IXICO's record describes an imaging core lab headquartered in the United Kingdom with a global footprint and a neuroimaging focus, with Phase I and Phase II listed. That makes it most relevant to neurology programmes measuring brain structure or change over time. Where to probe: if your programme runs into late phase, confirm its support beyond the phases listed, and ask how it harmonises sequences across scanner models.

4DMedical Clinical Trials

4DMedical Clinical Trials is listed as a medical imaging vendor with a respiratory focus, covering Phase I to Phase IV. Its stated best fit is trials needing imaging review, endpoint adjudication or core lab support. Where to probe: for a lung function or ventilation endpoint, ask how its imaging outputs are validated for your intended use and what acquisition demands they place on sites.

Activemetrics (Imaging)

Activemetrics' record describes imaging data analytics for clinical trial endpoint quantification, aimed at sponsors wanting data-driven imaging endpoint analytics. The record does not yet state its service model, headquarters or phase coverage, so the table shows those cells blank. Where to probe: ask whether it works as an analytics layer alongside a core lab or provides reads itself.

Judi (AG MedNet)

This record lists a medical imaging vendor with a generalist remit across Phase I to Phase IV, with a stated best fit of trials needing imaging review, endpoint adjudication or imaging AI support. Where to probe: ask how images move from sites into its system, how quality and completeness are tracked, and which parts of the review workflow it runs itself rather than enabling for other reviewers.

Aiforia Clinical Trials

Aiforia Clinical Trials is listed as a medical imaging vendor with a generalist remit across Phase I to Phase IV, and the same stated best fit of review, adjudication or imaging AI support. Where to probe: for any algorithm-assisted measurement, ask about its regulatory status for your intended use, the populations it was validated on, and how reader overrides are recorded.

Biomedical Systems Cardiac Safety

Biomedical Systems Cardiac Safety's record describes a cardiovascular focus, with a stated best fit of studies with ECG or cardiac-safety endpoint complexity. Its record lists cardiac endpoint depth as a strength and notes it is narrower than broad multi-modality imaging firms. Where to probe: if you also need oncology or neurology reads, decide early whether one partner or two is the better model.

Biospective Imaging

Biospective Imaging is listed across oncology, neurology and cardiovascular work, covering Phase I to Phase IV, with a stated best fit of studies with imaging endpoints or complex radiology workflows. Its record notes that operational complexity rises with modality mix, site variability and reader availability. Where to probe: ask how reader capacity is planned for your read volumes and timepoints.

Cardialysis

Cardialysis' record describes a cardiovascular imaging specialist covering Phase I to Phase IV, with a stated best fit of trials needing imaging review, endpoint adjudication or core lab support. Where to probe: ask which cardiac modalities and endpoints it reads in live studies, and how its adjudication process is documented for inspection.

Chondrometrics

Chondrometrics is listed with a focus on quantitative cartilage and bone imaging for trials, covering Phase I to Phase IV. That positions it for musculoskeletal programmes in which a quantitative structural measurement carries the endpoint. Where to probe: ask how its measurement methods are validated, how reader or algorithm consistency is monitored over a long study, and what acquisition protocol it needs from sites.

Engagement and pricing models

Imaging engagements are usually built from several components: study setup, including the imaging charter and acquisition manual; site qualification and training; per-scan or per-timepoint handling for transfer, quality control and archiving; per-read fees that differ by read type; adjudication where readers disagree; and data management and transfer of derived endpoints. Analytics, reprocessing and post-study archive access are often priced separately.

The main cost drivers are the number of sites and scanner types, timepoints per participant, the read design (one reader, two readers with adjudication, or audit reads only), urgency of eligibility and safety reads, and the length of retention. Agree in advance how re-reads, protocol amendments that add timepoints, and sites that fail qualification will be charged.

Questions to put in your RFP

• Which indications, modalities and assessment types do you support in live studies today?
• How are readers qualified before they touch study data, and how is drift monitored during the trial?
• How are disagreements between readers adjudicated, and by whom?
• Which computer-assisted tools are cleared for the intended use, and how are overrides recorded?
• What are your turnaround commitments for eligibility, safety and batched efficacy reads?
• How do you qualify sites whose scanners or protocols do not initially meet the imaging charter?
• What does site onboarding involve, and how long does qualification of a typical site take?
• What documentation package would an inspector receive for a single read, end to end?
• In which formats are raw images and derived data exported, and at what cost?
• How long do you retain an inspection-ready archive, and who pays for access after closure?

Due-diligence red flags

• Reference experience described only in terms of study counts, with no indication or modality detail.
• Reader qualification and adjudication processes that cannot be shown in documentation.
• Algorithms described without clarity on regulatory status or validation populations.
• Turnaround commitments absent from the contract or unmeasured during the study.
• Archive and export terms deferred to a later discussion.
• Site qualification treated as the sponsor's problem.
• A demonstration built on pristine single-scanner data rather than messy multi-site reality.
• No named owner when problems surface mid-study, or performance reporting that hides query queues.

Shortlist on Clinical Vendor Compare

Start in the vendor directory and filter for imaging to see every listed provider. Open profiles to check product type and stated focus, then place a few side by side on the compare page to separate imaging core labs from full-service CROs with imaging arms. Imaging often travels with laboratory work, so also read the guide to central laboratory vendors; if imaging endpoints feed an adaptive or late-phase design, see the guide to biometrics partners for late-phase trials. When your requirements are clear, use the sponsor RFP tool to brief vendors. If you have worked with an imaging partner on a trial, please write a review: published reviews are what give the next buyer an evidence base.